References

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

10.1136/gutjnl-2020-323888 · 2021 · External reference

Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load

10.1016/j.jhep.2021.04.051 · 2021 · External reference

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion

2024 · External reference

Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles

10.1128/jvi.00430-14 · 2014 · External reference

Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss

10.1136/gutjnl-2023-330577 · 2024 · External reference

Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

10.1002/hep.27102 · 2014 · External reference

Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta

10.1111/jvh.13366 · 2020 · External reference

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy

10.1002/ueg2.70153 · 2026 · External reference

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

2025 · External reference

EASL Clinical Practice Guidelines on hepatitis delta virus

10.1016/j.jhep.2023.05.001 · 2023 · External reference

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation

10.1016/j.jhep.2011.06.016 · 2012 · External reference

Virological and clinical characteristics of delta hepatitis in Central Europe

10.1111/j.1365-2893.2009.01144.x · 2009 · External reference

Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes

10.1002/hep.31214 · 2020 · External reference

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis

10.1016/j.jhep.2020.04.008 · 2020 · External reference

High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan

10.1111/liv.70799 · 2026 · External reference

Double reflex testing for anti-HDV antibody following an HBsAg-positive test result and HDV RNA in those anti-HDV positive: a global systematic review and meta-analysis

10.1016/j.eclinm.2025.103708 · 2026 · External reference

Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D

10.1097/hep.0000000000001786 · 2026 · External reference

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial

10.1016/j.jhep.2026.03.046 · 2026 · External reference

Unresolved reference

External reference

Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies

10.1016/j.jhep.2023.11.019 · 2024 · External reference

Immunology of hepatitis D virus infection: General concepts and present evidence

10.1111/liv.15424 · 2023 · External reference

Unresolved reference

External reference

Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection

2026 · External reference

Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024

10.1111/liv.70189 · 2025 · External reference

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

10.1016/j.jhep.2024.12.044 · 2025 · External reference

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

10.1016/j.jhep.2024.01.035 · 2024 · External reference